Healthcare

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full...

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

Amphista Therapeutics announces new AMX-883 data to be presented at the ASH Annual Meeting and Exposition and provides a business progress update

AMX-883 shows synergistic efficacy in combination with venetoclax in vivo and prevents the emergence of resistance to venetoclax in vitro, addressing...

error: Content is protected !!